These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37694500)

  • 1. Neurological burden and outcomes of excessive β-lactam serum concentrations of critically ill septic patients: a prospective cohort study.
    Zerbib Y; Gaulin C; Bodeau S; Batteux B; Lemaire-Hurtel AS; Maizel J; Kontar L; Bennis Y
    J Antimicrob Chemother; 2023 Nov; 78(11):2691-2695. PubMed ID: 37694500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients.
    Beumier M; Casu GS; Hites M; Wolff F; Cotton F; Vincent JL; Jacobs F; Taccone FS
    Minerva Anestesiol; 2015 May; 81(5):497-506. PubMed ID: 25220556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).
    Guilhaumou R; Benaboud S; Bennis Y; Dahyot-Fizelier C; Dailly E; Gandia P; Goutelle S; Lefeuvre S; Mongardon N; Roger C; Scala-Bertola J; Lemaitre F; Garnier M
    Crit Care; 2019 Mar; 23(1):104. PubMed ID: 30925922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance.
    Teshome BF; Vouri SM; Hampton N; Kollef MH; Micek ST
    Pharmacotherapy; 2019 Mar; 39(3):261-270. PubMed ID: 30506852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
    Ulldemolins M; Vaquer S; Llauradó-Serra M; Pontes C; Calvo G; Soy D; Martín-Loeches I
    Crit Care; 2014 Jun; 18(3):227. PubMed ID: 25042938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.
    Dilworth TJ; Schulz LT; Micek ST; Kollef MH; Rose WE
    Crit Care Explor; 2022 Jul; 4(7):e0726. PubMed ID: 35815181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study.
    Carrié C; Petit L; d'Houdain N; Sauvage N; Cottenceau V; Lafitte M; Foumenteze C; Hisz Q; Menu D; Legeron R; Breilh D; Sztark F
    Int J Antimicrob Agents; 2018 Mar; 51(3):443-449. PubMed ID: 29180280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-control study of drug monitoring of β-lactams in obese critically ill patients.
    Hites M; Taccone FS; Wolff F; Cotton F; Beumier M; De Backer D; Roisin S; Lorent S; Surin R; Seyler L; Vincent JL; Jacobs F
    Antimicrob Agents Chemother; 2013 Feb; 57(2):708-15. PubMed ID: 23147743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are β-lactam concentrations adequate in severe sepsis and septic shock in children?
    Chosidow A; Benaboud S; Beranger A; Zheng Y; Moulin F; Dupic L; Renolleau S; Treluyer JM; Oualha M
    Therapie; 2020; 75(6):633-640. PubMed ID: 32593420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
    Dhaese S; Van Vooren S; Boelens J; De Waele J
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1155-1164. PubMed ID: 32597263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric aztreonam is associated with increased mortality compared to beta-lactams in septic shock.
    Jaffa RK; Hammer J; Medaris LA; Anderson WE; Heffner AC; Pillinger KE
    Am J Emerg Med; 2021 Oct; 48():255-260. PubMed ID: 34004470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.
    Hayashi Y; Lipman J; Udy AA; Ng M; McWhinney B; Ungerer J; Lust K; Roberts JA
    Int J Antimicrob Agents; 2013 Feb; 41(2):162-6. PubMed ID: 23153962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the practical impact of adjusting beta-lactam dosages based on therapeutic drug monitoring in critically ill adult patients: a systematic review and meta-analysis of randomized clinical trials and observational studies.
    Gulyás E; Horváth IL; Engh MA; Bunduc S; Dembrovszky F; Fehérvári P; Bánvölgyi A; Csupor D; Hegyi P; Karvaly GB
    Sci Rep; 2024 Apr; 14(1):7793. PubMed ID: 38565898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study.
    Huttner A; Von Dach E; Renzoni A; Huttner BD; Affaticati M; Pagani L; Daali Y; Pugin J; Karmime A; Fathi M; Lew D; Harbarth S
    Int J Antimicrob Agents; 2015 Apr; 45(4):385-92. PubMed ID: 25656151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial.
    Ewoldt TMJ; Abdulla A; Rietdijk WJR; Muller AE; de Winter BCM; Hunfeld NGM; Purmer IM; van Vliet P; Wils EJ; Haringman J; Draisma A; Rijpstra TA; Karakus A; Gommers D; Endeman H; Koch BCP
    Intensive Care Med; 2022 Dec; 48(12):1760-1771. PubMed ID: 36350354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.